Is Calix a biotech stock? Today's Investor Presentation confirms that it is.
Set to become a multi-faceted conglomerate, Calix is claiming key territory in the hospital space - an ability to suppress golden staph and e-coli scourges by >90%.
A check of Slide 44 gives a glimpse of the group's plans. We're looking at a longer term strategy that may result in submissions to the FDA.
In the shorter term, discovery, development and possible partnering promises a steady, biotech-related news flow.
Calix claims >90% win over Golden Staph
Add CXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
0.010(0.74%) |
Mkt cap ! $247.6M | |||
| Open | High | Low | Value | Volume |
| $1.36 | $1.43 | $1.34 | $933.6K | 681.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9250 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.37 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.37 | $1.43 | $1.34 | 103239 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| CXL (ASX) Chart |